The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
Open accessAbstract
BACKGROUND: Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose of intravenous alteplase may improve recovery along with a reduced risk of intracerebral hemorrhage. METHODS: Using a 2-by-2 quasi-factorial open-label design, we randomly assigned 3310 patients who were eligible for thrombolytic therapy (median age, 67 years; 63% Asian) to low-dose intravenous alteplase (0.6 mg per kilogram of body weight) or the standard dose (0.9 mg per kilogram); patients underwent randomization within 4.5 hours after the onset of stroke. The primary objective was to determine whether the low dose would be noninferior to the standard dose with respect to the primary outcome of death or disability at 90 days, which was defined by scores of 2 to 6 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Secondary objectives were to determine whether the low dose would be superior to the standard dose with respect to centrally adjudicated symptomatic intracerebral hemorrhage and whether the low dose would be noninferior in an ordinal analysis of modified Rankin scale scores (testing for an improvement in the distribution of scores). The trial included 935 patients who were also randomly assigned to intensive or guideline-recommended blood-pressure control. RESULTS: The primary outcome occurred in 855 of 1607 participants (53.2%) in the low-dose group and in 817 of 1599 participants (51.1%) in the standard-dose group (odds ratio, 1.09; 95% confidence interval [CI], 0.95 to 1.25; the upper boundary exceeded the noninferiority margin of 1.14; P=0.51 for noninferiority). Low-dose alteplase was noninferior in the ordinal analysis of modified Rankin scale scores (unadjusted common odds ratio, 1.00; 95% CI, 0.89 to 1.13; P=0.04 for noninferiority). Major symptomatic intracerebral hemorrhage occurred in 1.0% of the participants in the low-dose group and in 2.1% of the participants in the standard-dose group (P=0.01); fatal events occurred within 7 days in 0.5% and 1.5%, respectively (P=0.01). Mortality at 90 days did not differ significantly between the two groups (8.5% and 10.3%, respectively; P=0.07). CONCLUSIONS: This trial involving predominantly Asian patients with acute ischemic stroke did not show the noninferiority of low-dose alteplase to standard-dose alteplase with respect to death and disability at 90 days. There were significantly fewer symptomatic intracerebral hemorrhages with low-dose alteplase. (Funded by the National Health and Medical Research Council of Australia and others; ENCHANTED ClinicalTrials.gov number, NCT01422616.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Emberson, J., Lees, K. R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60584-5 · Cited by 2,737
Self-citationWahlgren, N., Ahmed, N., Dávalos, A., Ford, G. A., Grond, M., Hacke, W., Hennerici, M. G., Kaste, M., Kuelkens, S., Larrue, V., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60149-4 · Cited by 2,379
Banks, J. L., & Marotta, C. A. (2007) · Stroke · doi:10.1161/01.str.0000258355.23810.c6 · Cited by 2,253
von Kummer, R., Broderick, J. P., Campbell, B. C. V., Demchuk, A., Goyal, M., Hill, M. D., Treurniet, K. M., Majoie, C. B. L. M., Marquering, H. A., Mazya, M. V., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.010049 · Cited by 1,409
Self-citationThrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370
Wardlaw, J. M., Murray, V., Berge, E., del Zoppo, G., Sandercock, P., Lindley, R. L., & Cohen, G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60738-7 · Cited by 1,010
Self-citationSaver, J. L., Fonarow, G. C., Smith, E. E., Reeves, M. J., Grau-Sepulveda, M. V., Pan, W., Olson, D. M., Hernandez, A. F., Peterson, E. D., & Schwamm, L. H. (2013) · JAMA · doi:10.1001/jama.2013.6959 · Cited by 870
Cited by
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Self-citationEuropean Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Hankey, G. J. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,226
Campbell, B. C. V., & Khatri, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31179-x · Cited by 1,116
Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials
Broderick, J. P., Adeoye, O., & Elm, J. (2017) · Stroke · doi:10.1161/strokeaha.117.017866 · Cited by 807
Self-citationYaghi, S., Willey, J. Z., Cucchiara, B., Goldstein, J. N., Gonzales, N. R., Khatri, P., Kim, L. J., Mayer, S. A., Sheth, K. N., & Schwamm, L. H. (2017) · Stroke · doi:10.1161/str.0000000000000152 · Cited by 545
Boulanger, J., Lindsay, M., Gubitz, G., Smith, E., Stotts, G., Foley, N., Bhogal, S., Boyle, K., Braun, L., Goddard, T., et al. (2018) · International Journal of Stroke · doi:10.1177/1747493018786616 · Cited by 380
Recent advances in the management of acute ischemic stroke
Chang, P., & Prabhakaran, S. (2017) · F1000Research · doi:10.12688/f1000research.9191.1 · Cited by 379
Update on Treatment of Acute Ischemic Stroke
Rabinstein, A. A. (2020) · Continuum · doi:10.1212/con.0000000000000840 · Cited by 293
Anderson, C. S., Huang, Y., Lindley, R. I., Chen, X., Arima, H., Chen, G., Li, Q., Billot, L., Delcourt, C., Bath, P. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30038-8 · Cited by 278
Self-citationMitchell, P. J., Yan, B., Churilov, L., Dowling, R. J., Bush, S. J., Bivard, A., Huo, X. C., Wang, G., Zhang, S. Y., Ton, M. D., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00564-5 · Cited by 229
Self-citationIncreasing value and reducing waste in stroke research
Berge, E., Salman, R. A.-S., van der Worp, H. B., Stapf, C., Sandercock, P., Sprigg, N., Macleod, M. R., Kelly, P. J., Nederkoorn, P. J., Ford, G. A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30078-9 · Cited by 41
Metadata
- Authors
- Anderson, C. S., Robinson, T., Lindley, R. I., Arima, H., Lavados, P. M., Lee, T.-H., Broderick, J. P., Chen, X., Chen, G., Sharma, V. K., Kim, J. S., Thang, N. H., Cao, Y., Parsons, M. W., Levi, C., Huang, Y., Olavarría, V. V., Demchuk, A. M., Bath, P. M., Donnan, G. A., Martins, S., Pontes-Neto, O. M., Silva, F., Ricci, S., Roffe, C., Pandian, J., Billot, L., Woodward, M., Li, Q., Wang, X., Wang, J., & Chalmers, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-16
- Volume
- 374
- Issue
- 24
- Pages
- 2313-2323
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2350862887
- Cited by
- 442
- References
- 30
- FWCI
- 49.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.